secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001628280-26-028128
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026
--------------------------------------------------------------------------------

- Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.
- Trading will be suspended at open on May 5, 2026; company plans to appeal before Nasdaq Hearings Panel.
- Common stock approved for quotation on OTCQB Venture Market starting May 5, 2026 under symbol SGMO.
- Company previously received two compliance periods but remained non-compliant with bid price rule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828026028128/0001628280-26-028128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828026028128/sgmo-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-028128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer